Education
About Us
Working with TipRanks
Follow Us
MTRA - ETF AI Analysis
Top Page
Invesco International Growth Focus ETF (MTRA)
Rating:59Neutral
Price Target:―
Positive Factors
Broad International Diversification
The fund spreads its investments across many countries, including the U.S., UK, France, Japan, and others, which helps reduce the impact of problems in any single market.
Balanced Sector Mix
Holdings are spread across Industrials, Health Care, Consumer, Technology, and Financials, so the ETF is not overly tied to the fortunes of just one industry.
Generally Positive Recent Performance
The ETF has shown steady gains so far this year and in recent months, suggesting its strategy has been working in the current market environment.
Negative Factors
Moderately High Expense Ratio
The fund’s fee is on the higher side for an ETF, which slightly reduces the net return investors keep over time.
Mixed Performance Among Top Holdings
While some major positions like ASML, Alibaba, and Ferguson have been strong, others such as Booking Holdings, AstraZeneca, and Tencent have been weak, creating uneven contribution to returns.
Concentration in a Few Sectors
A large portion of assets is in Industrials and Health Care, which could hurt performance if these areas fall out of favor.
MTRA vs. SPDR S&P 500 ETF (SPY)
AUM138.91M
RegionGlobal Ex-U.S.
Expense Ratio0.54%
Beta1.24
IssuerInvesco
Inception DateJun 11, 2025
Dividend YieldN/A
Asset ClassEquity
Index TrackedNo Underlying Index
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume90
30 Day Avg. Volume5,114
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
30.41Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering47
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
MTRA Summary
The Invesco International Growth Focus ETF (MTRA) is an actively managed fund that looks for fast-growing companies outside the U.S., rather than tracking a set index. It invests across many countries and sectors, with top holdings including well-known names like ASML and Alibaba. Investors might consider MTRA if they want long-term growth potential and diversification beyond the U.S. stock market, especially in innovative international businesses. However, because it focuses on growth stocks in foreign markets, its price can be more volatile and can go up and down significantly with global market conditions.
How much will it cost me?The Invesco International Growth Focus ETF (MTRA) has an expense ratio of 0.54%, which means you’ll pay $5.40 per year for every $1,000 invested. This is higher than average because the fund is actively managed, requiring more research and analysis to select stocks. Active management often leads to higher costs compared to passively managed funds that track an index.
What would affect this ETF?The Invesco International Growth Focus ETF (MTRA) could benefit from global economic recovery and increased demand for innovative technologies, healthcare advancements, and industrial growth, as these sectors make up a significant portion of its holdings. However, potential risks include geopolitical tensions, regulatory changes in key regions, and currency fluctuations, which could negatively impact the performance of its international investments. Additionally, rising interest rates or economic slowdowns in major markets could challenge growth-focused companies in the ETF.
MTRA Top 10 Holdings
MTRA leans heavily into non-U.S. growth stories, with Europe and Asia doing much of the heavy lifting. ASML has been a standout engine for returns, riding strong demand for chipmaking equipment, while defense giant BAE Systems and pharma leader AstraZeneca are also pulling their weight with steady, upward trends. HSBC adds a solid financials backbone with improving sentiment. On the flip side, Chinese tech names like Tencent and Alibaba have been losing steam lately, acting as a drag. Overall, the fund tilts toward industrials and health care, with a global ex-U.S. growth flavor.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| ASML Holding NV | 4.17% | $5.76M | €438.37B | 77.64% | 76 Outperform | |
| Siemens | 3.57% | $4.93M | €168.54B | -4.31% | 74 Outperform | |
| HSBC Holdings | 3.46% | $4.78M | £214.86B | 46.35% | 80 Outperform | |
| Resmed | 3.44% | $4.75M | $36.85B | 6.89% | 76 Outperform | |
| Tencent Holdings | 3.15% | $4.35M | HK$4.66T | 5.05% | 75 Outperform | |
| BAE Systems | 3.03% | $4.19M | $88.45B | 49.14% | 61 Neutral | |
| Alibaba | 3.03% | $4.18M | $276.76B | 0.08% | 68 Neutral | |
| Booking Holdings | 3.02% | $4.17M | $140.65B | -0.23% | 63 Neutral | |
| Ferguson PLC | 3.01% | $4.15M | £33.40B | 29.54% | ― | |
| Lonza Group Ltd | 2.89% | $3.99M | CHF33.99B | -7.35% | 71 Outperform |
MTRA Technical Analysis
Negative
―
Price Trends
26.59
Negative
26.28
Negative
Market Momentum
-0.44
Positive
34.07
Neutral
9.36
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MTRA, the sentiment is Negative. The current price of undefined is equal to the 20-day moving average (MA) of 26.05, equal to the 50-day MA of 26.59, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -0.44 indicates Positive momentum. The RSI at 34.07 is Neutral, neither overbought nor oversold. The STOCH value of 9.36 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for MTRA.
MTRA Peer Comparison
Comparison Results
Performance Comparison
MTRA
Invesco International Growth Focus ETF
24.92
-0.18
-0.72%
APIE
ActivePassive International Equity ETF
―
―
―
MFSI
MFS Active International ETF
―
―
―
OSEA
Harbor International Compounders ETF
―
―
―
QLTI
GMO International Quality ETF
―
―
―
AVDS
Avantis International Small Cap Equity ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents